Effusion Reduction after Early Trastuzumab Deruxtecan Therapy for Unresectable HER2-Low Breast Cancer in an Older Patient: A Case Report
T-DXd is potentially a safe and effective treatment option for older patients with HER2-low breast cancer and for those with impaired ADL. Further accumulation of cases and investigations of long-term outcomes are warranted.
Authors
- Ayaka Akabane
- Takayuki Tanaka (ORCID: https://orcid.org/0000-0001-8018-7984)
- Fuyuhiko Motoi (ORCID: https://orcid.org/0000-0001-7601-8395)
- Masaaki Kawai (ORCID: https://orcid.org/0000-0003-1383-0487)
- Mitsuru Futakuchi (ORCID: https://orcid.org/0000-0001-8647-583X)
- Kazushi Suzuki (ORCID: https://orcid.org/0000-0003-4953-8656)
- Ayaka Goto
Institutions
- Yamagata University (JP)
Publication Details
- Journal
- Surgical Case Reports
- Published
- 2025-01-01
- DOI
- https://doi.org/10.70352/scrj.cr.25-0466
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00